Drug Discovery Online: Does Targeting Macrophages Hold The Key For Treating Cancer?

Pheast cofounder and CEO, Roy Maute, speaks with Drug Discovery Online about the growing potential of macrophage checkpoint inhibition as a next wave in immuno-oncology, and how he believes the company’s CD24 targeting approach may overcome limitations of existing therapies, particularly in hard-to-treat solid tumors with high unmet need. Maute also provides perspective on the clinical and biological factors required for success, underscoring Pheast Therapeutics’ strategy to advance differentiated macrophage-directed therapies as a complementary and potentially transformative modality within cancer treatment.

Read the full article here.